Docking screens for novel ligands conferring new biology: Miniperspective

JJ Irwin, BK Shoichet - Journal of medicinal chemistry, 2016 - ACS Publications
It is now plausible to dock libraries of 10 million molecules against targets over several days
or weeks. When the molecules screened are commercially available, they may be rapidly …

Clinical development of histone deacetylase inhibitors as anticancer agents

DC Drummond, CO Noble, DB Kirpotin… - Annu. Rev …, 2005 - annualreviews.org
▪ Abstract Acetylation is a key posttranslational modification of many proteins responsible for
regulating critical intracellular pathways. Although histones are the most thoroughly studied …

Inside HDAC with HDAC inhibitors

P Bertrand - European journal of medicinal chemistry, 2010 - Elsevier
Histone deacetylase inhibitors are a large group of diverse molecules intrinsically able to
inhibit cell proliferation in various cancer cell lines. Their apoptotic effects have been linked …

Histone deacetylase inhibitors: from bench to clinic

M Paris, M Porcelloni, M Binaschi… - Journal of medicinal …, 2008 - ACS Publications
The interest in histone deacetylase (HDACa) inhibitors began almost 30 years ago during
some studies designed to understand why dimethyl sulfoxide (DMSO) caused terminal …

Histone deacetylation in epigenetics: an attractive target for anticancer therapy

A Mai, S Massa, D Rotili, I Cerbara… - Medicinal research …, 2005 - Wiley Online Library
The reversible histone acetylation and deacetylation are epigenetic phenomena that play
critical roles in the modulation of chromatin topology and the regulation of gene expression …

Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl) pyrrolyl hydroxyamides

A Mai, S Massa, R Pezzi, S Simeoni… - Journal of medicinal …, 2005 - ACS Publications
Chemical manipulations performed on aroyl-pyrrolyl-hydroxyamides (APHAs) led to
(aryloxopropenyl) pyrrolyl hydroxamates 2a− w, and their inhibition against maize HDACs …

5-Aroylindoles act as selective histone deacetylase 6 inhibitors ameliorating Alzheimer's disease phenotypes

HY Lee, SJ Fan, FI Huang, HY Chao… - Journal of Medicinal …, 2018 - ACS Publications
This paper reports the development of a series of 5-aroylindolyl-substituted hydroxamic
acids. N-Hydroxy-4-((5-(4-methoxybenzoyl)-1 H-indol-1-yl) methyl) benzamide (6) has …

Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties

A Mai, D Rotili, D Tarantino, P Ornaghi… - Journal of medicinal …, 2006 - ACS Publications
Starting from a yeast phenotypic screening performed on 21 compounds, we described the
identification of two small molecules (9 and 18) able to significantly reduce the S. cerevisiae …

Epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors

A Mai, D Cheng, MT Bedford, S Valente… - Journal of medicinal …, 2008 - ACS Publications
A number of new compounds bearing two ortho-bromo-and ortho, ortho-dibromophenol
moieties linked through a saturated/unsaturated, linear/(poly) cyclic spacer (compounds 1 …

Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells

E Di Bello, V Sian, G Bontempi, C Zwergel… - European Journal of …, 2023 - Elsevier
After over 30 years of research, the development of HDAC inhibitors led to five FDA/Chinese
FDA-approved drugs and many others under clinical or preclinical investigation to treat …